Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin on Divarasib PK
NCT06835465Phase 1Completed
- Sponsor
- Genentech
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of divarasib in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (2 arms), sponsored by Genentech. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-time Curve Extrapolated to Infinity and 1 more. Started Feb 2025; status: completed.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06835465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06835465.